Clinical Trials Browser

Phase 1 × INDUSTRY × BI 2536 × Clear all

NCT00243087 2024-12-20

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02211859 2024-12-20

Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

Phase 1 Completed

70 enrolled

Tumor-Agnostic

Neoplasms

NCT02215044 2014-08-13

Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 1 Terminated

12 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02211833 2014-08-08

Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer

Phase 1 Completed

41 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung